1. Lisi Zeng, Xubo Huang, Yun Tian, Jinxia Huang, Jiali Luo, Hongsheng Tang, Quanxing Liao,
Ziying Lei, Weiwen Cui, Qianghua Xia, Tianpei Guan, Jin Li, Shuzhong Cui. Tumor mutational burden
associated with response to hyperthermic intraperitoneal chemotherapy. Frontiers in Oncology. 2022 Mar
8;12:796263.
2. Lisi Zeng, Quanxing Liao, Xiaohui Zeng, Jiacai Ye, Xianzi Yang, Siyu Zhu, Hongsheng Tang,
Gaojie Liu, Weiwen Cui, Shaohua Ma, Shuzhong Cui. Noncoding RNAs and hyperthermic intraperitoneal
chemotherapy in advanced gastric cancer. Bioengineered. 2022 Feb;13(2):2623-2638.
3. Xian-Zi Yang, Lei Ma, Shu-Xian Fang, Ye Song, Si-Yu Zhu, Chuan Jin, Wei Liu, Qin Lu, Li-Si
Zeng, Shu-Zhong Cui. Construction of a competing endogenous RNA network and identification of potential
regulatory axes in gastric cancer chemoresistance. Pathology Research and Practice. 2022 Jun; 234:153904.
doi: 10.1016/j.prp.2022.153904.
4. Lisi Zeng, Quanxing Liao, Haoran Zhao, Shengwei Jiang, Xianzi Yang, Hongsheng Tang, Qingjun
He, Xiansheng Yang, Shuxian Fang, Jinfu He, Weiwen Cui, Laiqiang Huang, Shaohua Ma, Shuzhong Cui.
Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer
organoids, Cancer Biology
&
Medicine. 2021 Mar 12;18(3):750-762
5. Guan T, Cheng M, Zeng L, Chen X, Xie Y, Lei Z, Ruan Q, Wang J, Cui S, Sun Y, Li H.
Engineering the Redox-Driven Channel for Precisely Regulating Nanoconfined Glutathione Identification
and Transport. ACS Appl Mater Interfaces. 2021 Oct 20;13(41):49137-49145.
6. Wen-Qi Cai , Li-Si Zeng, Li-Feng Wang, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Zi-Wen
Han, Yang Zhou, Shao-Li Huang, Xian-Wang Wang, Xiao-Chun Peng, Ying Xiang, Zhaowu Ma,
Shu-Zhong Cui, Hong-Wu Xin. The latest battles between EGFR monoclonal antibodies and resistant tumor
cells. Frontiers in Oncology. 2020 Jul 24;10:1249.
7. Xian-Zi Yang, Tian-Tian Cheng, Qing-Jun He, Zi-Ying Lei, Jun Chi, Zhen Tang, Quan-Xing Liao,
Hong Zhang, Li-Si Zeng, Shu-Zhong Cui. LINC01133 as ceRNA inhibits gastric cancer progression by
sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer. 2018 Aug
22;17(1):126.
8. Ying-Ying Liang, Xu-Bin Deng, Li-Si Zeng, Xian-Tao Lin, Xun-Fan Shao, Zhi-Wen Mo, Ya-wei
Yuan. RASSF6-mediated inhibition of Mcl-1 through JNK activation improves the anti-tumor effects of
sorafenib in renal cell carcinoma. Cancer Letters. 2018 Sep 28;432:75-83.